Abstract Details

Title Burden of Comorbid Depression and Anxiety on Migraine-specific Health-related Quality of Life in Adult Migraine Patients in the United States

Topic Headache

Presentation(s) P12 - Poster Session 12 (12:00 PM-1:00 PM)

Poster/Presentation
Number 7-010

Objective The objective of this study was to examine the impact of comorbid depression and/or anxiety on migraine-specific health-related quality of life (HRQoL) outcomes in the real world from a patient perspective.

Background Depression and anxiety are often comorbid with migraine and are associated with reduced quality of life and increased overall disease burden.

Design/Methods Data were drawn from the 2017 US Adelphi Migraine Disease Specific Programme, which included primary care physicians and neurologists and their consulting migraine patients. Patients completed a questionnaire that included validated measures of migraine-specific HRQoL and general quality of life, such as the Migraine Disability Assessment (MIDAS), Migraine-Specific Questionnaire (MSQ), and the EuroQol 5-Dimension 5-Level (EQ-5D-5L). Depression/anxiety was derived from the EQ-5D domain, and patients were categorized as experiencing none, slight, or moderate-to-severe (moderate+) depression/anxiety. Linear regressions were performed on the EQ-5D visual analog scale (VAS) and MSQ domains to assess the relationship between the severity of anxiety/depression and headache days on HRQoL outcomes. Poisson regressions were performed on the square root of MIDAS being closest to normality from a number of transformations.

Results 873 persons with migraine from the Adelphi Migraine Disease Specific Programme provided information on depression/anxiety. More severe anxiety/depression and an increasing number of headache days were associated with poorer MSQ scores, including the overall MSQ score and all 3 MSQ domains (P<0.01). Similarly, more severe anxiety/depression and an increasing number of headache days were associated with more severe disability, based on MIDAS scores (P<0.001). Worse anxiety/depression was also associated with worse overall quality of life, based on EQ-5D VAS scores (P<0.001).

Conclusions In patients with migraine, higher levels of depression/anxiety were associated with significant reductions in both migraine-specific (MSQ) and generic (EQ-5D) HRQoL and increases in disability (MIDAS).

Authors/Disclosures
Dawn C. Buse, PhD (Dawn C. Buse, PhD) PRESENTER	Dr. Buse has received personal compensation for serving as an employee of Vector Psychometric Group. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranicsa. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Buse has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Reports. The institution of Dr. Buse has received research support from Amgen. The institution of Dr. Buse has received research support from FDA. The institution of Dr. Buse has received research support from National Headache Foundation.
Ravi Iyer	No disclosure on file
Joshua M. Cohen, MD	No disclosure on file
James Jackson (Adelphi Real World)	James Jackson has nothing to disclose.
Verena Ramirez Campos, MD (Teva)	Dr. Ramirez Campos has received personal compensation for serving as an employee of teva.
Sarah Cotton	Sarah Cotton has nothing to disclose.
	No disclosure on file
Richard B. Lipton, MD, F�鶹��ýӳ�� (Albert Einstein College of Medicine)	Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clexio. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has or had stock in Biohaven.Dr. Lipton has or had stock in Manistee.Dr. Lipton has or had stock in Axon.Dr. Lipton has or had stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.

�鶹��ýӳ��

�鶹��ýӳ��